{"id":30845,"date":"2019-05-15T12:00:00","date_gmt":"2019-05-15T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/"},"modified":"2019-05-15T12:00:00","modified_gmt":"2019-05-15T12:00:00","slug":"consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/es\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/","title":{"rendered":"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma"},"content":{"rendered":"
\n
\n
\n

Biol\u00f3gicos para la RSCcPN con o sin asma<\/h2>\n

Las terapias novedosas, como los biol\u00f3gicos dirigidos al tipo 2, son opciones de tratamiento emergentes para pacientes con enfermedades respiratorias inflamatorias cr\u00f3nicas, que satisfacen las necesidades de pacientes gravemente no controlados. La mayor\u00eda de los pacientes con rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN) y m\u00e1s de la mitad de los pacientes con asma muestran una firma inflamatoria de tipo 2 en la mucosa sinonasal y\/o los pulmones. <\/p>\n

EUFOREA organiz\u00f3 una reuni\u00f3n multidisciplinar de expertos para debatir el posicionamiento de los biol\u00f3gicos en las v\u00edas de atenci\u00f3n para pacientes con RSCcPN con y sin asma com\u00f3rbida.<\/p>\n

Desc\u00e1rguelo ahora para obtener informaci\u00f3n completa.<\/p>\n

ART\u00cdCULO DE ACCESO ABIERTO<\/strong><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n


\n
\n<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Biol\u00f3gicos para la RSCcPN con o sin asma Las terapias novedosas, como los biol\u00f3gicos dirigidos al tipo 2, son opciones de tratamiento emergentes para pacientes con enfermedades respiratorias inflamatorias cr\u00f3nicas, que satisfacen las necesidades de pacientes gravemente no controlados. La mayor\u00eda de los pacientes con rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN) y m\u00e1s de la mitad de los pacientes con asma muestran una firma inflamatoria de tipo 2 en la mucosa sinonasal y\/o los pulmones. EUFOREA organiz\u00f3 una reuni\u00f3n multidisciplinar de expertos para debatir el posicionamiento de los biol\u00f3gicos en las v\u00edas de atenci\u00f3n para pacientes con RSCcPN con y sin asma com\u00f3rbida. Desc\u00e1rguelo ahora para obtener informaci\u00f3n completa. ART\u00cdCULO DE ACCESO ABIERTO<\/p>\n","protected":false},"author":1,"featured_media":30865,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[268],"tags":[176,177,178,179,210,274],"class_list":["post-30845","news","type-news","status-publish","has-post-thumbnail","hentry","category-publicaciones","tag-profesionales-sanitarios","tag-asma","tag-rscpn","tag-biologicos","tag-enfermedades-respiratorias-cronicas-erc","tag-publicaciones"],"yoast_head":"\nConsenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma\" \/>\n<meta property=\"og:description\" content=\"Biol\u00f3gicos para la RSCcPN con o sin asma Las terapias novedosas, como los biol\u00f3gicos dirigidos al tipo 2, son opciones de tratamiento emergentes para pacientes con enfermedades respiratorias inflamatorias cr\u00f3nicas, que satisfacen las necesidades de pacientes gravemente no controlados. La mayor\u00eda de los pacientes con rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN) y m\u00e1s de la mitad de los pacientes con asma muestran una firma inflamatoria de tipo 2 en la mucosa sinonasal y\/o los pulmones. EUFOREA organiz\u00f3 una reuni\u00f3n multidisciplinar de expertos para debatir el posicionamiento de los biol\u00f3gicos en las v\u00edas de atenci\u00f3n para pacientes con RSCcPN con y sin asma com\u00f3rbida. Desc\u00e1rguelo ahora para obtener informaci\u00f3n completa. ART\u00cdCULO DE ACCESO ABIERTO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/\",\"name\":\"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"datePublished\":\"2019-05-15T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"width\":427,\"height\":280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/elige-tu-camino\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/","og_locale":"es_ES","og_type":"article","og_title":"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma","og_description":"Biol\u00f3gicos para la RSCcPN con o sin asma Las terapias novedosas, como los biol\u00f3gicos dirigidos al tipo 2, son opciones de tratamiento emergentes para pacientes con enfermedades respiratorias inflamatorias cr\u00f3nicas, que satisfacen las necesidades de pacientes gravemente no controlados. La mayor\u00eda de los pacientes con rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN) y m\u00e1s de la mitad de los pacientes con asma muestran una firma inflamatoria de tipo 2 en la mucosa sinonasal y\/o los pulmones. EUFOREA organiz\u00f3 una reuni\u00f3n multidisciplinar de expertos para debatir el posicionamiento de los biol\u00f3gicos en las v\u00edas de atenci\u00f3n para pacientes con RSCcPN con y sin asma com\u00f3rbida. Desc\u00e1rguelo ahora para obtener informaci\u00f3n completa. ART\u00cdCULO DE ACCESO ABIERTO","og_url":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","og_image":[{"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/","url":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/","name":"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","datePublished":"2019-05-15T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","width":427,"height":280},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/consenso-de-euforea-sobre-biologicos-para-la-rsccpn-con-o-sin-asma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.euforea.org\/es\/elige-tu-camino\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"Consenso de EUFOREA sobre biol\u00f3gicos para la RSCcPN con o sin asma"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/30845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/comments?post=30845"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/30845\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media\/30865"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media?parent=30845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/categories?post=30845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/tags?post=30845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}